Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.48 |
| ▸ | NOS2 | P35228 | 6/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 5/20 | 0.42 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226337 | 0.92 | CCNK (0.43) | HCAR3NOS2JAK3PRKAA2JAK2 | |
| SCHEMBL4219722 | 0.85 | HCAR3 (0.45) | HCAR3JAK3JAK2CCNKCDK12 | |
| SCHEMBL4223312 | 0.84 | FAAH (0.53) | — | |
| SCHEMBL4230600 | 0.82 | NOS3 (0.57) | NOS2PRKAA2NOS1NOS3CCNK | |
| SCHEMBL4222650 | 0.81 | HCAR3 (0.49) | HCAR3NOS2JAK3NOS1NOS3 | |
| SCHEMBL1460502 | 0.81 | CCR6 (0.54) | HCAR3NOS2NOS1NOS3CCNK | |
| SCHEMBL4218644 | 0.81 | ACHE (0.58) | PRKAA2HRH3 | |
| SCHEMBL8104999 | 0.80 | HCAR3 (0.56) | HCAR3CYP11B1CYP11B2 | |
| SCHEMBL1577712 | 0.78 | WNT3A (0.40) | HRH3 | |
| SCHEMBL28767580 | 0.78 | USP30 (0.52) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | HCAR3 137/4885NOS2 3761/4885CYP11B1 1468/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | HCAR3 148/4885NOS2 3815/4885CYP11B1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.